AstraZeneca's newly acquired Alexion will buy the remaining equity in rare disease specialist Caelum Biosciences in a deal that could be worth up to $500 million.
Alexion and development partner Caelum Biosciences have begun late-stage trials of their light-chain (AL) amyloidosis drug CAEL-101, snapping at the heels of Janssen and its recently-filed
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl